Fig 1: Effects of ADAM12 on oncogenic signaling pathways in the human colorectal cancer cells. Representative western blot images and semi-quantification graphs for the phosphorylation levels of PDK1, GSK-3β and AKT in AV-transfected or AS-transfected DLD1 or SW480 cells. Data are presented as the mean ± SD (n=3). *P<0.05. ADAM12, a disintegrin and metalloprotease 12; PDK1, phosphoinositide-dependent protein kinase 1; GSK-3β, glycogen synthase kinase-3β; EV, empty pcDNA6-myc vector; AV, ADAM12-pcDNA6-myc construct; SS, scrambled siRNA; AS, ADAM12 siRNA; siRNA, small interfering RNA; p-, phosphorylated; T-, total.
Fig 2: Effects of ADAM12 on the epithelial-mesenchymal transition process in a mouse model of peritoneal metastasis. The same number of EV AV construct-, Ssh- or Ash-transfected SW480 cells were injected intraperitoneally into non-obese diabetic/severe combined immunodeficiency mice (n=6/group). The mice injected with the AV-transfected cells showed a significant increase in ADAM12 expression and a decrease in E-cadherin expression compared with in the mice injected with the EV-transfected cells. In addition, the mice injected with the Ash-transfected cells had a significant decrease in ADAM12 expression and an increase in E-cadherin expression compared with in the mice injected with the Ssh-transfected cells. Data are presented as the mean ± SD (n=3). *P<0.05. ADAM12, a disintegrin and metalloprotease 12; EV, empty pcDNA6-myc vector; AV, ADAM12-pcDNA6-myc construct; Ssh, Scrambled pGFP-C-shLenti vector; Ash, ADAM12-pGFP-C-shLenti construct.
Fig 3: Effects of ADAM12 on the invasion and migration of human colorectal cancer cells. (A) Invasive cells transfected with the AV construct or AS were counted. The number of invasive AS-transfected cells was significantly lower than that of SS-transfected DLD1 and SW480 cells. (B) Wound healing assay was performed on cells transfected with the AV construct or AS, and relative healing distances are presented. The artificial wound gap in the plates of the SS-transfected cells was significantly narrower than that in the AS-transfected cells at 24 h for DLD1 cells and 48 h for SW480 cells. Gap distance was normalized to 10 mm. Data are presented as the mean ± SD (n=3). *P<0.05. ADAM12, a disintegrin and metalloprotease 12; EV, empty pcDNA6-myc vector; AV, ADAM12-pcDNA6-myc construct; SS, scrambled siRNA; AS, ADAM12 siRNA; siRNA, small interfering RNA.
Fig 4: Effects of ADAM12 on the metastasis of human CRC cells in the mouse model of peritoneal metastasis. The same number of EV-, AV construct-, Ssh- or Ash-transfected SW480 cells were injected intraperitoneally into non-obese diabetic/severe combined immunodeficiency mice (n=6/group). (A) Representative images of peritoneal nodules in the mice injected with EV-, AV-, Ssh- and Ash-transfected cells. After 28 days, the (B) number of peritoneal nodules, (C) PCI and (D) tumor weight in the mice injected with the AV-transfected cells were higher than in the mice injected with the EV-transfected cells. By contrast, the number of peritoneal nodules, PCI and tumor weight in the mice injected with the Ash-transfected cells were lower than in the mice injected with the Ssh-transfected cells. Data are presented as the median ± interquartile range. *P<0.05. ADAM12, a disintegrin and metalloprotease 12; EV, empty pcDNA6-myc vector; AV, ADAM12-pcDNA6-myc construct; Ssh, scrambled pGFP-C-shLenti vector; Ash, ADAM12-pGFP-C-shLenti construct; PCI, peritoneal carcinomatosis index.
Fig 5: Effects of ADAM12 expression on the proliferation of human CRC cells. (A) Protein expression levels of ADAM12 following transfection with various concentrations of the ADAM12 pcDNA6-myc construct. (B) Protein expression levels of ADAM12 post-transfection in CRC cell lines. Western blotting revealed that the ADAM12 protein was overexpressed or knocked down using an AV construct or AS, respectively. (C) Effect of ADAM12 expression on the proliferation of human CRC cells, as determined using a WST-1 assay. Data are presented as the mean ± SD (n=3). *P<0.05. ADAM12, a disintegrin and metalloprotease 12; CRC, colorectal cancer; EV, empty pcDNA6-myc vector; AV, ADAM12-pcDNA6-myc construct; SS, scrambled siRNA; AS, ADAM12 siRNA; siRNA, small interfering RNA.
Supplier Page from OriGene Technologies for ADAM12 Human shRNA Plasmid Kit (Locus ID 8038)